Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Ondansetron use for intractable nausea and vomiting in AIDS patients.
Int Conf AIDS. 1996 Jul 7-12;11(2):108 (abstract no. We.B.3296). Unique Identifier : AIDSLINE MED/96923647 Balano KB; San Francisco General Hospital, San Francisco, CA, USA. Fax: 415); 476-3454. E-mail: kbalano@itsa.ucsf.edu.
Abstract:
Problem: Intractable nausea and vomiting from various causes, including gastrointestinal disease and drug induced emesis, is a major source of morbidity for many patients with AIDS and contributes to significant weight loss. Ondansetron, a selective serotonin antagonist, is a highly effective therapy for preventing nausea and vomiting associated with cancer chemotherapy. Ondansetron's efficacy in treating nausea and vomiting in AIDS patients not receiving chemotherapy has not been well studied. Methods: 22 AIDS patients receiving oral ondansetron therapy from Sept 1993 - Oct 1994 were identified from outpatient pharmacy record. Medical records of eighteen of these patients were available for review. Two patients were currently receiving ondansetron for chemotherapy-induced nausea and vomiting and were excluded from analysis. Charts for the remaining sixteen were reviewed for 1) cause of vomiting, 2) previous antiemetic use, 3) dosage of ondansetron, 4) duration of treatment, and 5) response to ondansetron therapy. Cost of therapy was analyzed using the drug acquisition cost to San Francisco General Hospital. Results: Although the specific causes of vomiting in the sixteen evaluable patients varied substantially, just over half of the patients had significant gastrointestinal disease alone or with medication-induced emesis as a possible etiology. All patients had received a trial of other antiemetic agents. 25% of the patients had maximized doses of their antiemetic regimen prior to beginning ondansetron therapy. An ondansetron dosage of 8 mg TID was most commonly prescribed. 9 of 16 patients received ondansetron therapy for greater than or equal one month and half of the individual prescriptions were for more than a 2 week supply of medication. 8 patients had a complete response to ondansetron therapy, and 7 had a minor response with some persistent nausea and vomiting. 1 patient continued to have nausea and vomiting despite aggressive therapy with ondansetron and other antiemetics. Conclusion: Oral ondansetron was effective in treating intractable nausea and vomiting in this small group of patients. Because ondansetron is a very expensive drug, healthcare providers need to be able to appropriately prescribe other drugs as first-line therapy. Ondansetron remains an excellent alternative for patients unresponsive to standard antiemetic therapy.
Keywords: *Acquired Immunodeficiency Syndrome/COMPLICATIONS *Antiemetics/THERAPEUTIC USE *Nausea/DRUG THERAPY *Ondansetron/THERAPEUTIC USE *Vomiting/DRUG THERAPY 970130
M9713406
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
